Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
7.83
-0.04 (-0.51%)
Feb 21, 2025, 4:00 PM EST - Market closed
Amneal Pharmaceuticals Employees
Amneal Pharmaceuticals had 7,850 employees as of December 31, 2023. The number of employees increased by 250 or 3.29% compared to the previous year.
Employees
7,850
Change (1Y)
250
Growth (1Y)
3.29%
Revenue / Employee
$341,455
Profits / Employee
-$23,497
Market Cap
2.43B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
AMRX News
- 3 days ago - Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide - Business Wire
- 24 days ago - Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025 - Business Wire
- 4 weeks ago - Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin - Business Wire
- 2 months ago - Amneal to Participate at Upcoming Investor Conferences - Business Wire
- 3 months ago - Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist - Business Wire
- 3 months ago - Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Amneal Reports Third Quarter 2024 Financial Results - Business Wire
- 4 months ago - Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets - Business Wire